Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.

"CONFLICT OF INTEREST A.V., T.S., A.S., A.L.: none. M.D.: reports advisory fees from Echo Pharma and Robarts Clinical Trials, Inc., speaker fees from Janssen, Merck & Co., Inc., Pfizer, Takeda and Tillotts Pharma, and nonfinancial support from Dr. Falk Pharm. F.S: Advisory Boards Takeda, Galapagos. K.G.: has received grants from Pfizer Inc. and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, ImmunicTherapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis and Takeda; and speaker's honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis, Takeda and Tillotts. C.P.: received grants or contracts from Takeda, Pliant, and Gilead Sciences; consulting fees from Pliant and Shire (Takeda); and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events from Takeda, Tillotts Pharma, and Pfizer outside of the submitted work. J.G.: has served as a speaker for: Dr. Falk, GlaxoSmithKline, Janssen‐Cilag. J.H.: speaker's fees from Abbvie, Janssen, Takeda; consulting fees from Alimentiv Inc. G.T.: none. J.J.: has served on advisory boards and as a speaker or consultant for Abbvie, Amgen, Ferring, Fresenius, Janssen, MSD, Pfizer, Takeda. A.G.L. F.H.: Frank Hoentjen has served on advisory boards and as a speaker for Abbvie, Janssen‐Cilag, MSD, Takeda, Celltrion, Teva, Sandoz and Dr Falk Funding (Grants/Honoraria): Takeda, Janssen‐Cilag, Abbvie Consulting Fees: Celgene. N.B.: has served as a speaker for AbbVie and MSD and has served as a consultant and/or principal investigator for TEVA Pharma BV and Takeda. He has received a [unrestricted] research grant from Dr. Falk, TEVA Pharma BV, MLDS and Takeda. All outside the submitted work. G.Dijkstra.: has received speakers fees from Janssen‐Cilag, Pfizer, Takeda and Abbvie. B.O.: has served as speaker for Galapagos, MSD, Janssen and received unrestricted grants from Takeda, Pfizer, Galapagos, Ferring, Celltrion and Abbvie. M.L.: has served as a speaker and/or principal investigator for: Abbvie, Alimentiv, Bristol Myers Squibb, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Galapagos, Gilead, GlaxoSmithKline, Janssen‐Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, Tramedico. He has received research grants from AbbVie, Merck Sharp & Dohme, Dr Falk, Achmea healthcare, Galapagos and ZonMW. A.M.: has served as speaker for: Galapagos, Janssen‐Cilag, Takeda, Tramedico. She has received research grants from Cablon, Galapagos, Nestle, Norgine and ZonMW. G.D.: Consultancy for Abbvie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, Glaxo Smith Kline, Gossamerbio, Pfizer, Immunic, Johnson and Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus laboratories, Prometheus Biosciences, Progenity, Protagonist. Speaker's bureau for Abbvie, Arena, Galapagos, Gilead, Pfizer, BMS, Takeda."

"FUNDING INFORMATION The ICC fellow [T.S.] is sponsored by AbbVie, Pfizer, Takeda, Celgene, Janssen Pharmaceutica, Teva Pharmaceutical Industries, MLDS, Cablon Medical, Ferring pharmaceuticals, Mundipharma, Dr. Falk Pharma, Sandoz and Tramedico."